Baseline and Amphetamine-Stimulated Dopamine Activity Are Related in Drug-Naïve Schizophrenic Subjects

• Published in: Biological psychiatry (1969) Vol. 65; no. 12; pp. 1091 - 1093
• Main Authors: Abi-Dargham, Anissa, van de Giessen, Elsmarieke, Slifstein, Mark, Kegeles, Lawrence S., Laruelle, Marc
• Format: Journal Article
• Language: English
• Published: New York, NY Elsevier Inc 15.06.2009; Elsevier
• Subjects: Adult; Adult and adolescent clinical studies; alpha-Methyltyrosine; amphetamine; Amphetamine - pharmacology; Benzamides; Biological and medical sciences; D2 receptor; dopamine; Dopamine - metabolism; Dopamine Uptake Inhibitors - pharmacology; Enzyme Inhibitors; Female; Humans; Image Processing, Computer-Assisted; Male; Medical sciences; Neostriatum - diagnostic imaging; Neostriatum - metabolism; Neuropharmacology; Pharmacology. Drug treatments; Psychiatric/Mental Health; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer; Psychoanaleptics: cns stimulant, antidepressant agent, nootropic agent, mood stabilizer..., (alzheimer disease); Psychology. Psychoanalysis. Psychiatry; Psychopathology. Psychiatry; Psychopharmacology; Psychoses; Pyrrolidines; Radiopharmaceuticals; Receptors, Dopamine D2 - drug effects; Receptors, Dopamine D2 - metabolism; Schizophrenia; Schizophrenia - diagnostic imaging; Schizophrenia - metabolism; SPECT; Tomography, Emission-Computed, Single-Photon; Young Adult; α-MPT; amphetamine; D2 receptor; schizophrenia; dopamine; SPECT; α-MPT; Amphetamine derivatives; Radionuclide study; Human; Dopamine; CNS stimulant; Psychotropic; Schizophrenia; Single photon emission tomography; Catecholamine; Photon; Psychosis; D2 Dopamine receptor; Neurotransmitter; Amfetamine
• ISSN: 0006-3223; 1873-2402; 1873-2402
• DOI: 10.1016/j.biopsych.2008.12.007

Previous studies demonstrated increased striatal dopamine (DA) release after amphetamine challenge and increased striatal baseline occupancy of D2 receptors in patients with schizophrenia compared with control subjects. We report here on the relationship between these two aspects of DA release in drug-naïve patients with schizophrenia (SCZ) and matched healthy control subjects (HC). Six drug-naïve SCZ and eight HC underwent single-photon emission computed tomography (SPECT) scans after bolus followed by constant infusion of (S)-(-)-3-[123I]iodo-2-hydroxy-6-methoxy-N-[(1-ethyl-2-pyrrolidinyl)methyl]benzamide ([123I]IBZM) under three conditions to determine the equilibrium specific to non-displaceable binding potential (BP ND) for striatal D2 at baseline, after amphetamine administration and after DA depletion. Amphetamine induced decrease in BP ND was positively correlated with BP ND increase after DA depletion in SCZ ( p = .02) but not in HC ( p = .44). Additionally, both were significantly increased. In drug-naïve patients with schizophrenia but not in control subjects, stimulated and baseline DA release are both increased and positively correlated. At the neuronal level this association suggests that capacity for storage in presynaptic terminals, measured with the amphetamine paradigm, and baseline intrasynaptic DA release, measured with the α-methyl-para-tyrosine (αMPT) paradigm, are associated in schizophrenia, both consistent with increased midbrain DA cells activity.